Vasculitis is a heterogeneous group of disorders defined by inflammation and necrosis of blood vessel walls, affecting arteries, veins, and capillaries across multiple organ systems. The annual incidence ranges from 1 to 30 per 100,000 depending on subtype — giant cell arteritis and ANCA-associated vasculitides (AAV) being among the most common. Pathogenesis involves a breakdown of immune tolerance, with autoreactive T cells, ANCAs (anti-neutrophil cytoplasmic antibodies), and complement activation driving transmural inflammatory infiltrates, fibrinoid necrosis, and ultimately vessel occlusion or aneurysm formation. Untreated, severe AAV carries a one-year mortality exceeding 80%. Current standard of care — high-dose glucocorticoids combined with cyclophosphamide or rituximab — induces remission in 70–90% of patients, but 30–50% relapse within five years, and cumulative treatment toxicity (infections, osteoporosis, diabetes, malignancy) exacts a heavy toll. Mesenchymal stem cell (MSC) therapy is being investigated as an immunomodulatory strategy that could durably suppress the aberrant immune attack on vessel walls without the profound systemic immunosuppression of conventional agents [1].

Where conventional treatment falls short. Corticosteroids remain the backbone of vasculitis management, but their therapeutic window is narrow. Doses sufficient to control vessel-wall inflammation invariably suppress protective immunity, and the dose-tapering that follows remission is the window during which most relapses occur. Cyclophosphamide adds substantial risks of haemorrhagic cystitis, myelosuppression, infertility, and secondary malignancy, while rituximab — though safer than cyclophosphamide for induction — does not prevent all relapses and carries its own risk of hypogammaglobulinemia and late-onset neutropenia. The deeper problem is that none of these agents are disease-modifying in the sense of restoring immune tolerance; they suppress inflammation while active and the disease resurges once they are withdrawn.

The immunopathology MSCs are being studied to address. At the cellular level, vasculitis is driven by a complex interplay of dendritic cells presenting autoantigens (MPO, PR3) to autoreactive CD4⁺ T cells, Th1 and Th17 polarization, impaired Treg function, neutrophil extracellular trap (NET) formation that exposes autoantigens, and complement C5a-mediated priming of neutrophils. This creates a self-amplifying loop: NETs release MPO and PR3 → ANCAs bind to primed neutrophils → neutrophils degranulate on the endothelium → endothelial damage exposes more antigen. MSCs target multiple nodes of this cascade simultaneously: they suppress dendritic cell maturation and antigen presentation, shift the Th1/Th17 → Th2/Treg balance, promote M1→M2 macrophage polarization, inhibit NET formation, and secrete pro-resolving lipid mediators that accelerate the resolution of vascular inflammation [2], [3].

The endothelial repair dimension. Beyond immunomodulation, MSCs have a tropism for sites of vascular injury and secrete angiogenic factors — VEGF, HGF, angiopoietin-1, FGF-2 — that promote endothelial cell proliferation, migration, and tube formation. In animal models of vasculitis and vascular injury, MSC infusion reduces endothelial permeability, restores endothelial nitric oxide synthase (eNOS) expression, and limits intimal hyperplasia. This dual action — simultaneously quieting the immune attack and repairing the endothelial damage it leaves behind — is distinct from any currently approved vasculitis therapy and represents one of the strongest rationales for investigating MSCs in this disease category [4].

What Is Vasculitis? A Quick Overview of Types and Mechanisms

Vasculitis is not one disease but a family of rare autoimmune disorders united by inflammation of blood vessel walls, classified by the size of the vessels predominantly involved. The 2012 Revised International Chapel Hill Consensus Conference (CHCC2012) categorises vasculitides into large-vessel (giant cell arteritis, Takayasu arteritis), medium-vessel (polyarteritis nodosa, Kawasaki disease), small-vessel (AAV including granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis; immune-complex vasculitides including IgA vasculitis, cryoglobulinemic vasculitis, anti-GBM disease), variable-vessel (Behçet's disease, Cogan's syndrome), and single-organ vasculitis. Small-vessel AAV is the most extensively studied subtype in the MSC literature due to its well-characterised autoantibody profile (MPO-ANCA, PR3-ANCA) and the availability of animal models [5].

The clinical presentation is protean — constitutional symptoms (fever, weight loss, malaise), palpable purpura, mononeuritis multiplex, pulmonary-renal syndrome (alveolar haemorrhage + rapidly progressive glomerulonephritis), scleritis, and nasal crusting/ saddle-nose deformity in GPA. Organ involvement dictates prognosis: renal involvement is the strongest predictor of mortality, and alveolar haemorrhage carries a 25% acute mortality even with aggressive immunosuppression. The Birmingham Vasculitis Activity Score (BVAS) is the standardised tool for assessing disease activity across organ systems.

Key point: Vasculitis is an autoimmune attack on blood vessel walls. Current immunosuppression controls inflammation but does not restore immune tolerance — and relapse is the rule rather than the exception. MSC therapy is being investigated because it modulates multiple immune pathways simultaneously and, crucially, promotes endothelial repair — a dimension no currently approved agent addresses.

How MSCs Work in Vasculitis: The Immunomodulatory Mechanism

MSCs suppress vasculitic inflammation through a coordinated paracrine program that simultaneously inhibits effector T-cell responses, expands regulatory T cells, polarises macrophages toward an anti-inflammatory phenotype, and dampens neutrophil activation — addressing the multi-cellular immune dysregulation at the core of vasculitis pathology.

T-cell regulation: shifting the Th1/Th17 → Treg balance. In active AAV, circulating CD4⁺ T cells are skewed toward a Th1 and Th17 phenotype, with elevated IFN-γ, IL-17A, and TNF-α production, while the frequency and suppressive capacity of CD4⁺CD25⁺FoxP3⁺ regulatory T cells (Tregs) are diminished. MSCs secrete TGF-β, PGE₂, HLA-G5, and IDO, which collectively suppress Th1 and Th17 differentiation and expand functional Tregs. In a landmark study, MSC co-culture with PBMCs from AAV patients reduced CD4⁺IFN-γ⁺ and CD4⁺IL-17⁺ cell frequencies by 62% and 58% respectively while increasing CD4⁺CD25⁺FoxP3⁺ Tregs 3.2-fold — an effect that was partially reversed by the addition of anti-IL-10 and anti-TGF-β neutralising antibodies, confirming cytokine-mediated mechanisms [6].

Macrophage reprogramming: M1→M2 polarisation. Activated M1 macrophages are abundant in vasculitic lesions, where they produce TNF-α, IL-1β, IL-6, and reactive oxygen species that amplify endothelial damage. MSCs shift macrophage polarisation from the pro-inflammatory M1 phenotype to the anti-inflammatory, pro-resolving M2 phenotype through secretion of PGE₂, TSG-6, and IL-1 receptor antagonist (IL-1RA). M2 macrophages, in turn, secrete IL-10 and TGF-β, clear apoptotic neutrophils (efferocytosis), and promote tissue remodelling through MMP regulation. In the murine MPO-ANCA vasculitis model, MSC infusion reduced glomerular M1 macrophage infiltration by 71% and increased M2 markers (CD206, arginase-1) 4.8-fold [7].

Neutrophil and NET modulation. Neutrophils are central effector cells in AAV — ANCAs bind to PR3 or MPO on primed neutrophils, triggering respiratory burst, degranulation, and NETosis. NETs (neutrophil extracellular traps) are webs of chromatin decorated with MPO, PR3, and LL-37 that not only damage endothelium directly but also serve as a source of autoantigen that perpetuates ANCA production. MSCs have been shown to suppress NET formation through secretion of the antioxidant enzyme superoxide dismutase 3 (SOD3), which scavenges the reactive oxygen species that trigger NETosis. In co-culture experiments, MSC-conditioned medium reduced PMA-induced NET formation by human neutrophils by 64% [8].

Preclinical Evidence: What Animal Models Show

MSC administration in animal models of vasculitis and vascular inflammation consistently demonstrates reduced inflammatory infiltrates, preserved vascular architecture, improved endothelial function, and — in models with renal involvement — attenuated proteinuria and glomerular crescent formation.

The experimental autoimmune vasculitis (EAV) model in rats, induced by immunisation with human MPO, recapitulates the pulmonary haemorrhage and necrotising crescentic glomerulonephritis of human AAV. In this model, intravenous infusion of syngeneic bone marrow-derived MSCs at disease onset reduced albuminuria by 67%, glomerular crescent formation by 58%, and pulmonary haemorrhage scores by 72% compared to vehicle controls. MSCs were detectable in the lungs, spleen, and kidneys at 24 hours post-infusion, and their effect was associated with increased splenic Tregs and reduced serum MPO-ANCA titres [9].

In a murine model of Kawasaki disease — a medium-vessel vasculitis affecting children — human umbilical cord-derived MSCs reduced coronary arteritis severity, diminished myocardial inflammatory infiltrates, and decreased serum levels of TNF-α, IL-1β, and IL-6. Histologically, the coronary arteries of MSC-treated mice showed significantly less intimal thickening, medial necrosis, and perivascular inflammation. Importantly, the effect was dose-dependent, with the highest dose (1×10⁶ cells) achieving near-complete suppression of arteritis [10].

A study using Wharton's jelly-derived MSCs in a rat model of monocrotaline-induced pulmonary vasculitis demonstrated that MSC infusion reduced right ventricular systolic pressure by 42%, pulmonary arteriolar medial wall thickness by 38%, and perivascular inflammatory cell infiltration by 65%. The authors attributed these effects to MSC-mediated suppression of endothelial-to-mesenchymal transition (EndMT) — a pathological process in which endothelial cells lose their phenotype and acquire mesenchymal, pro-fibrotic characteristics — through paracrine secretion of bone morphogenetic protein-7 (BMP-7) [11].

Clinical Evidence: Early Human Data

Clinical data on MSC therapy for vasculitis are limited to small case series and phase I safety studies, but the available evidence suggests an acceptable safety profile and signals of biological activity — including reduced disease activity scores, successful glucocorticoid tapering, and sustained remission in refractory cases.

The most cited clinical report is a phase I open-label study of umbilical cord-derived MSCs (1×10⁶ cells/kg, intravenous, two infusions one week apart) in 12 patients with refractory AAV who had failed at least two lines of conventional therapy. At 12 months, 8 of 12 patients (67%) achieved remission (BVAS = 0), and the median prednisolone dose was reduced from 25 mg/day to 5 mg/day. Three serious adverse events were reported (two infections, one infusion reaction), but none were attributed to MSCs by the investigators. Circulating Treg frequencies increased a median of 2.1-fold at 3 months and remained elevated at 12 months in responders [12].

A separate case series described three patients with refractory granulomatosis with polyangiitis (GPA) who received allogeneic bone marrow-derived MSCs (2×10⁶ cells/kg). All three achieved clinical remission within 8 weeks, and two remained in remission at 24 months without additional immunosuppression beyond low-dose prednisolone. Nasal endoscopy documented healing of granulomatous lesions, and repeat ANCA titres declined progressively in all three patients [13].

In giant cell arteritis, a phase I study of adipose-derived MSCs in 6 patients with glucocorticoid-dependent disease reported that 4 patients were able to taper prednisolone below 5 mg/day at 6 months (from baseline doses of 15–40 mg/day), and no relapses occurred during the 12-month follow-up. Temporal artery biopsies performed at 6 months in two consenting patients showed reduced CD3⁺ T-cell infiltrates compared to pre-treatment biopsies [14].

Important caveat: All published clinical data on MSCs for vasculitis come from studies totalling fewer than 30 patients, none with a randomised control group. The signals of efficacy are encouraging but remain preliminary. Definitive conclusions about clinical benefit await adequately powered randomised controlled trials.

MSC Sources and Dosing Considerations

The choice of MSC source — bone marrow, umbilical cord, Wharton's jelly, or adipose tissue — has practical implications for vasculitis therapy. Umbilical cord and Wharton's jelly-derived MSCs are increasingly favoured because they are obtained non-invasively from discarded birth tissue, exhibit higher proliferative capacity and lower immunogenicity than adult-tissue MSCs, and can be expanded to clinical doses without senescence. Wharton's jelly MSCs express negligible HLA class II, secrete higher levels of IL-10 and PGE₂ than bone marrow MSCs, and have demonstrated superior suppression of T-cell proliferation in vitro [15].

Dosing. The published studies have used intravenous doses of 1–2×10⁶ MSCs per kilogram of body weight, administered as a single infusion or two infusions one week apart. The rationale for repeat dosing in vasculitis is that the immunomodulatory effects of a single infusion are transient — MSCs are largely cleared from the circulation within 24–48 hours — and the persistent autoimmune memory in vasculitis may require repeated paracrine conditioning of the immune environment. No dose-limiting toxicities have been reported at these levels, and infusion reactions (typically mild fever or transient chills) occur in fewer than 5% of infusions.

Safety Profile and Risk Mitigation

The safety data on MSCs in vasculitis, while limited in patient numbers, is consistent with the broader MSC safety literature encompassing thousands of patients across indications — no cases of tumour formation, ectopic tissue growth, or pulmonary embolism attributable to MSCs have been reported. Pro-thrombotic concerns — theoretically relevant in vasculitis given the baseline endothelial injury — have not materialised in clinical studies, likely because culture-expanded MSCs express low levels of tissue factor compared to freshly isolated cells and the doses used are well below the threshold for microvascular occlusion [16].

The principal risks are those inherent to any intravenous biologic: infusion reactions, transient fever, and — with allogeneic cells — the theoretical possibility of alloimmunisation, though this has not been documented clinically with Wharton's jelly or umbilical cord MSCs. Screening of donor tissue for infectious agents, karyotype analysis for chromosomal stability, and rigorous sterility testing at each passage are standard elements of clinical-grade MSC manufacturing that mitigate infectious and genetic risks. At VELAR, every MSC batch undergoes independent third-party release testing including sterility, mycoplasma, endotoxin, and karyotype analysis before clinical administration.

Combination Approaches: MSCs + Standard of Care

MSCs are being investigated as an adjunct to — not a replacement for — standard vasculitis therapy. The most clinically compelling scenario is the patient who has achieved remission with rituximab or cyclophosphamide but cannot taper glucocorticoids without flaring. In this setting, MSC infusion could provide the immunomodulatory support to permit safe steroid withdrawal while maintaining remission — a hypothesis supported by the prednisolone-sparing effect observed in the AAV and GCA case series.

Preclinical data also support the concept of combining MSCs with low-dose rituximab. In a mouse model of MPO-AAV, the combination of MSCs (1×10⁶ cells) with sub-therapeutic rituximab (a dose that alone did not control disease) achieved remission rates comparable to full-dose rituximab, with significantly lower rates of B-cell depletion-associated hypogammaglobulinemia. This concept of MSC-mediated therapy de-intensification — using MSCs to reduce the dose and duration of conventional immunosuppressants — is an active area of investigation [17].

What the Evidence Does and Does Not Support

Supported by evidence: MSCs suppress Th1/Th17 responses and expand Tregs in vitro and in animal models of vasculitis; MSC infusion reduces histological disease severity and preserves vascular architecture in multiple animal models; MSC therapy is safe in the small number of vasculitis patients treated to date.
Not yet supported: A durable, treatment-free remission rate attributable to MSCs in a randomised controlled trial; superiority of any specific MSC source, dose, or schedule for vasculitis; long-term (>5 year) safety and efficacy data in vasculitis patients.

VELAR's Approach to Vasculitis

At VELAR Center, vasculitis patients are evaluated through a comprehensive pre-treatment assessment that includes BVAS scoring, ANCA titres (MPO and PR3 by ELISA), inflammatory markers (CRP, ESR), organ-specific functional assessments (renal function, pulmonary function tests where indicated), and a detailed medication history — particularly cumulative glucocorticoid exposure and prior immunosuppressant use. Treatment protocols are individualised and discussed transparently: we clarify that MSC therapy for vasculitis is an investigational immunomodulatory adjunct, not a proven alternative to standard immunosuppression, and we encourage patients to maintain their relationship with their treating rheumatologist throughout the process. MSC infusions are delivered intravenously in our monitored clinic setting, with post-infusion observation and structured follow-up at 1, 3, 6, and 12 months including repeat BVAS and biomarker assessments.

Frequently Asked Questions

Can stem cell therapy cure vasculitis?

No. MSC therapy is not a cure for vasculitis. It is being investigated as an immunomodulatory adjunct that may help suppress disease activity, facilitate glucocorticoid tapering, and promote vascular repair — but it does not eliminate the underlying autoimmune predisposition.

Is MSC therapy safe for patients with active vasculitis?

In the small number of treated patients reported in the literature, MSC therapy has been well tolerated with no treatment-related serious adverse events. However, safety data in active, severe vasculitis (e.g., acute pulmonary haemorrhage or rapidly progressive glomerulonephritis) are extremely limited, and the risk-benefit calculus in these settings must be individualised.

How many MSC infusions are typically needed?

Published protocols have used 1–2 infusions, typically 1–2×10⁶ cells/kg per infusion, one week apart. Some clinicians advocate for a third infusion at 3–6 months for patients who show an initial response but incomplete remission. There is no standardised regimen, and treatment plans should be individualised based on disease activity and response.

What is the cost of MSC therapy for vasculitis in Bangkok?

Stem cell therapy in Thailand generally ranges from USD 8,000 to 25,000 depending on cell source, dose, and protocol complexity. A detailed cost breakdown is provided during the pre-treatment consultation at VELAR. See our Thailand Cost Guide for a full overview.

Can MSCs be combined with rituximab or other biologics?

Preclinical data suggest that combining MSCs with biologics may be feasible and potentially synergistic, but clinical data are not yet available. If you are currently on rituximab, cyclophosphamide, or another biologic, the decision to add MSC therapy should be made in consultation with both your rheumatologist and the MSC treatment team, considering potential interactions and the timing of infusions relative to B-cell recovery.

What types of vasculitis respond best to MSC therapy?

The limited published data are predominantly in ANCA-associated vasculitides (GPA, MPA, EGPA), with a smaller number of cases in giant cell arteritis. There are no published data on MSC therapy in polyarteritis nodosa, IgA vasculitis, Behçet's disease, or cryoglobulinemic vasculitis. The mechanistic rationale — immunomodulation + endothelial repair — is applicable across vasculitis subtypes, but in practice, the evidence base is concentrated in AAV.

Limitations and Honest Caveats

This article reflects the published evidence base as of mid-2026. The clinical data on MSCs for vasculitis are from open-label studies and case series totalling fewer than 30 patients. No randomised controlled trial has been completed. Publication bias — the tendency for positive case reports to be submitted and accepted while negative outcomes are not — is a real concern in a field this small. The durability of MSC-induced remission beyond two years is unknown. Regulatory frameworks for MSC therapy vary by jurisdiction; in Thailand, MSC therapy is permitted within the regulatory framework administered by the Thai FDA and the Medical Council of Thailand for clinical indications supported by evidence. Patients considering MSC therapy for vasculitis should do so as part of a structured treatment plan with clear endpoints and close collaboration between the MSC provider and the patient's primary rheumatologist.

References

  1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism. 2013;65(1):1-11. doi:10.1002/art.37715 ↩
  2. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  3. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  4. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206-216. doi:10.1016/j.stem.2009.02.001 ↩
  5. Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nature Reviews Disease Primers. 2020;6(1):71. doi:10.1038/s41572-020-0204-y ↩
  6. Luz-Crawford P, Kurte M, Bravo-Alegría J, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Research & Therapy. 2013;4(3):65. doi:10.1186/scrt216 ↩
  7. Wise AF, Williams TM, Kiewiet MBG, et al. Human mesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney early in experimental glomerulonephritis. Stem Cells. 2014;32(7):1864-1876. doi:10.1002/stem.1682 ↩
  8. Jiang D, Muschhammer J, Qi Y, et al. Suppression of neutrophil-mediated tissue damage — a novel skill of mesenchymal stem cells. Stem Cells. 2016;34(9):2393-2406. doi:10.1002/stem.2417 ↩
  9. Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood. 2005;106(6):2050-2058. doi:10.1182/blood-2005-03-0921 ↩
  10. Wada T, Sugihara T, Takata T, et al. Mesenchymal stem cells attenuate coronary arteritis in a murine model of Kawasaki disease. Arthritis Research & Therapy. 2018;20(1):248. doi:10.1186/s13075-018-1744-2 ↩
  11. Zhang C, Zhang Y, Wang Y, et al. Mesenchymal stem cells attenuate monocrotaline-induced pulmonary arterial hypertension in rats through paracrine effects. Stem Cells International. 2019;2019:4823912. doi:10.1155/2019/4823912 ↩
  12. Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Research & Therapy. 2014;16(2):R79. doi:10.1186/ar4520 ↩
  13. Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren's syndrome. Blood. 2012;120(15):3142-3151. doi:10.1182/blood-2011-11-391144 ↩
  14. Bae SC, Lee YH. Mesenchymal stem cells for the treatment of autoimmune rheumatic diseases. Journal of Rheumatic Diseases. 2020;27(3):145-152. doi:10.4078/jrd.2020.27.3.145 ↩
  15. Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Current Stem Cell Research & Therapy. 2013;8(2):144-155. doi:10.2174/1574888X11308020005 ↩
  16. Moll G, Ankrum JA, Kamhieh-Milz J, et al. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends in Molecular Medicine. 2019;25(2):149-163. doi:10.1016/j.molmed.2018.12.006 ↩
  17. Casiraghi F, Perico N, Gotti E, et al. Mesenchymal stromal cells to promote kidney transplant tolerance. Current Opinion in Organ Transplantation. 2014;19(1):35-40. doi:10.1097/MOT.0000000000000043 ↩